Laurus Labs
BSE: 540222 | NSE: LAURUSLABS | ISIN: INE947Q01028 | SECTOR: Biotechnology & DrugsOpen
429.85High
431.45Low
423.20Prev Close
431.70P/E
-Median P/E
-P/B
-Median P/B
-Market Cap
230.22BVolume
69.61KVol. (20 day Avg.)
0PEG
-Div.Yield
-Bid
427.45Ask
427.95
Company Description
- Biotechnology & Drugs
BSE
540222NSE
LAURUSLABSISIN
INE947Q01028
Laurus Labs Limited is an India-based pharmaceutical and biotechnology company. The Company offers integrated portfolio of Active Pharma Ingredients (API) including intermediates, Generic Finished dosage forms (FDF) and Contract Research services to cater to the needs of the global pharmaceutical industry. The Company operates through three segments: Laurus Generics, Laurus Synthesis, and Laurus Bio. The Laurus Generics segment comprises API and FDF-Development, manufacture and sale of APIs and advanced intermediates and oral solid formulations/FDF. Laurus Synthesis segment comprises key starting materials (KSM), intermediates and APIs for new chemical entities (NCEs). Laurus Bio segment comprises recombinant products, animal origin free products for safer and viral free bio manufacturing. The Company operates through two geographical segments: Revenue from customers within India-Domestic, and Revenue from customers outside India-Exports. The Company sell its APIs in 56 countries.
Company Officers
Satyanarayana Chava
Chief Executive Officer, Executive DirectorVenkata Ravi Vantaram
Chief Financial Officer, Executive DirectorThomas Versosky
President - FDF, North AmericaKrishna Chava
Executive Vice President - Head of SynthesisV. Uma Maheswer Rao
Executive Vice President - Chemical R&DSrinivasa Suryadevara
Executive Vice President - Manufacturing and OperationsSita Ramaiah
Senior Vice President - FinanceNarasimha Chava
Senior Vice President - Human ResourceRajaram Iyer
Senior Vice President - Portfolio ManagementMartyn James Peck
Senior Vice President - Business Development